Literature DB >> 33496748

Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Connie M Arthur1, Jerry William L Allen1,2, Hans Verkerke1, Justin Yoo1, Ryan P Jajosky1, Kathryn Girard-Pierce1, Satheesh Chonat3, Patricia Zerra1,3, Cheryl Maier1, Jen Rha1, Ross Fasano1,3, Cassandra D Josephson1,3, John D Roback1, Sean R Stowell1,2.   

Abstract

Incompatible red blood cell (RBC) transfusion can result in life-threatening transfusion complications that can be challenging to manage in patients with transfusion-dependent anemia. However, not all incompatible RBC transfusions result in significant RBC removal. One factor that may regulate the outcome of incompatible RBC transfusion is the density of the incompatible antigen. Despite the potential influence of target antigen levels during incompatible RBC transfusion, a model system capable of defining the role of antigen density in this process has not been developed. In this study, we describe a novel model system of incompatible transfusion using donor mice that express different levels of the KEL antigen and recipients with varying anti-KEL antibody concentrations. Transfusion of KEL+ RBCs that express high or moderate KEL antigen levels results in rapid antibody-mediated RBC clearance. In contrast, relatively little RBC clearance was observed following the transfusion of KEL RBCs that express low KEL antigen levels. Intriguingly, unlike RBC clearance, loss of the KEL antigen from the transfused RBCs occurred at a similar rate regardless of the KEL antigen density following an incompatible transfusion. In addition to antigen density, anti-KEL antibody levels also regulated RBC removal and KEL antigen loss, suggesting that antigen density and antibody levels dictate incompatible RBC transfusion outcomes. These results demonstrate that antibody-induced antigen loss and RBC clearance can occur at distinct antigen density thresholds, providing important insight into factors that may dictate the outcome of an incompatible RBC transfusion.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33496748      PMCID: PMC7839377          DOI: 10.1182/bloodadvances.2020002695

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  74 in total

Review 1.  Signal transduction during Fc receptor-mediated phagocytosis.

Authors:  Erick García-García; Carlos Rosales
Journal:  J Leukoc Biol       Date:  2002-12       Impact factor: 4.962

2.  Antibody-mediated immune suppression by antigen modulation is antigen-specific.

Authors:  Cheryl L Maier; Amanda Mener; Seema R Patel; Ryan P Jajosky; Ashley L Bennett; Connie M Arthur; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood Adv       Date:  2018-11-13

Review 3.  Pathobiology of transfusion reactions.

Authors:  James C Zimring; Steven L Spitalnik
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

4.  Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Satheesh Chonat; Andreas Wieland; Manjula Santhanakrishnan; Jingchun Liu; Cheryl L Maier; Ryan P Jajosky; Kathryn Girard-Pierce; Ashley Bennett; Patricia E Zerra; Nicole H Smith; Jeanne E Hendrickson; Sean R Stowell
Journal:  JCI Insight       Date:  2018-11-15

5.  Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.

Authors:  E P Vichinsky; N L Luban; E Wright; N Olivieri; C Driscoll; C H Pegelow; R J Adams
Journal:  Transfusion       Date:  2001-09       Impact factor: 3.157

6.  Resistance of a subset of red blood cells to clearance by antibodies in a mouse model of incompatible transfusion.

Authors:  Justine S Liepkalns; Chantel M Cadwell; Sean R Stowell; Eldad A Hod; Steven L Spitalnik; James C Zimring
Journal:  Transfusion       Date:  2012-10-03       Impact factor: 3.157

7.  Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.

Authors:  Julie-An M Talano; Cheryl A Hillery; Jerome L Gottschall; Diane M Baylerian; J Paul Scott
Journal:  Pediatrics       Date:  2003-06       Impact factor: 7.124

8.  Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death.

Authors:  Philippe Chadebech; Anoosha Habibi; Ruben Nzouakou; Dora Bachir; Natacha Meunier-Costes; Philippe Bonin; Martine Rodet; Btissam Chami; Frederic Galacteros; Philippe Bierling; France Noizat-Pirenne
Journal:  Transfusion       Date:  2009-04-28       Impact factor: 3.157

Review 9.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18

10.  Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease.

Authors:  Satheesh Chonat; Sara Graciaa; H Stella Shin; Joanna G Newton; Maa-Ohui Quarmyne; Jeanne Boudreaux; Amy Tang; Patricia E Zerra; Margo R Rollins; Cassandra D Josephson; Clark Brown; Clinton H Joiner; Ross M Fasano; Sean R Stowell
Journal:  Haematologica       Date:  2020-12-01       Impact factor: 9.941

View more
  2 in total

1.  Examination of Whole-Cell Galectin Binding by Solid Phase and Flow Cytometric Analysis.

Authors:  Anne Leppänen; Connie M Arthur; Sean R Stowell; Richard D Cummings
Journal:  Methods Mol Biol       Date:  2022

2.  Antibodies against biotin-labeled red blood cells can shorten posttransfusion survival.

Authors:  Donald M Mock; Sean R Stowell; Robert S Franco; Svetlana V Kyosseva; Demet Nalbant; Robert L Schmidt; Gretchen A Cress; Ronald G Strauss; José A Cancelas; Melissa von Goetz; Anne K North; John A Widness
Journal:  Transfusion       Date:  2022-03-11       Impact factor: 3.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.